MCCP
EPZM

Mission Creek Capital Partners’s Epizyme, Inc EPZM Stock Holding History

Mission Creek Capital Partners’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-24,687
Closed -$396K – 206
2020
Q2 		$396K Buy
+24,687
New +$431K 0.21% 113

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Mission Creek Capital Partners's EPZM Position: Q3 2020 in Review

Mission Creek Capital Partners sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 24,687 shares — an estimated $396K sold.

Mission Creek Capital Partners first reported a position in EPZM in Q2 2020 and held it in 1 quarter. The position peaked at $396K in Q2 2020. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

  • Mission Creek Capital Partners reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
  • Mission Creek Capital Partners sold 24,687 Epizyme, Inc shares in Q3 2020, an estimated $396K.
  • Mission Creek Capital Partners first reported a position in Epizyme, Inc in Q2 2020 and held it in 1 quarter.
  • Mission Creek Capital Partners's Epizyme, Inc position peaked at $396K in Q2 2020.
  • 151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Mission Creek Capital Partners's 13F filing for Q3 2020, filed 13 Nov 2020.